Mablink Bioscience Enters an Agreement to be Acquired by Lilly
The pending acquisition reflects the potential of Mablink’s existing pipeline and proprietary PSARLink™ technology for development of...
top of page
A wholly owned subsidiary of Eli Lilly and Company
MBK-103
our lead ADC candidate
-
Validated druggable target: FR⍺
-
Potential to address:
-
Ovarian Cancer,
-
Triple Negative Breast Cancer,
-
Non-Small Cell Lung Cancer,
-
Colorectal Cancer
-
-
Exatecan (anti topo-I) as payload
-
Excellent pharmacological profile thanks to PSARLink™
Clinical trials planned to start in 2024 based on promising preclinical results.
bottom of page